连续与连续的对比. 固定的2年持续时间 免疫检查点抑制剂 治疗非小细胞肺癌患者:单一机构数据库分析
Haruki Kobayashi1, Kazushige Wakuda1, Tateaki Naito2
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan; Division of Respiratory Medicine, Nihon University School of Medicine, Tokyo, Japan.
Clinical lung cancer
|July 5, 2023
概括
对于晚期非小细胞肺癌 (NSCLC),持续免疫检查点抑制剂 (ICI) 治疗超过两年并没有改善结果,但增加了不良事件. 对NSCLC患者的最佳ICI持续时间需要进一步调查.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床研究 临床研究
背景情况:
- 对于晚期非小细胞肺癌 (NSCLC) 的免疫检查点抑制剂 (ICI) 治疗的最佳持续时间尚未确定.
- 临床试验通常使用2年固定的持续时间或持续的ICI治疗,直到疾病进展.
研究的目的:
- 评估ICI治疗持续时间 (2年固定或连续) 与高级NSCLC患者预后之间的关联.
- 为了比较不同ICI治疗持续时间之间的治疗失败的时间和与治疗相关的不良事件.
主要方法:
- 425名在2019年8月31日之前接受ICI治疗的NSCLC患者的医疗记录的回顾性审查.
- 基于治疗持续时间的治疗失败时间 (TTF) 和与治疗相关的不良事件的分析.
主要成果:
- 在接受治疗超过2年的患者和在2年内停止治疗的患者之间,没有观察到超过24个月的治疗失败时间 (TTF-24) 的显著差异.
- 与治疗相关的不良事件发生率在接受ICI治疗超过2年的患者中较高.
结论:
- 延长免疫检查点抑制剂 (ICI) 治疗超过2年并没有显著延长晚期非小细胞肺癌 (NSCLC) 治疗失败的时间.
- 较长的ICI治疗持续时间 (>2年) 与治疗相关不良事件的发生率增加有关.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
相关概念视频
01:27Tumor Immunotherapy
573
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K